Contents hide 1 About Fruquintinib 2 Approval 2.1 November 9, 2023 2.2 June 21, 2024 2.3 September 24, 2024 About Fruquintinib Fruquintinib (Fruzaqla)  sold under the brand name 爱优特 in china, is an oral, highly selective, small molecule VEGF receptor inhibitor. Because of the kinase selectivity of Fruzaqla, the risk of off-target toxicity is less than the risk with multikinase inhibitors, including regorafenib. Fruquintinib продается под торговой маркой Fruzaqla в США Fruquintinib продается под торговой маркой ELUNATE в Гонконге Fruquintinib продается под торговой маркой 爱优特 в Китае Approval November 9, 2023 The FDA has approved fruquintinib (Fruzaqla) to treat adults with metastatic … Continue reading Fruzaqla (Fruquintinib)